Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
Loading...
Embargo End Date
ICR Authors
Authors
Bughda, R
Dimou, P
D'Souza, RR
Klampatsa, A
Dimou, P
D'Souza, RR
Klampatsa, A
Document Type
Journal Article
Date
2021-01-01
Date Accepted
2021-07-20
Abstract
Fibroblast activation protein (FAP) is a membrane protease that is highly expressed by cancer-associated fibroblasts (CAFs). FAP can modulate the tumor microenvironment (TME) by remodeling the extracellular matrix (ECM), and its overexpression on CAFs is associated with poor prognosis in various cancers. The TME is in part accountable for the limited efficacy of chimeric antigen receptor (CAR)-T cell therapy in treatment of solid tumors. Targeting FAP with CAR-T cells is one of the strategies being researched to overcome the challenges in the TME. This review describes the role of FAP in the TME and its potential as a target in CAR-T cell immunotherapy, summarizes the preclinical studies and clinical trials of anti-FAP-CAR-T cells to date, and reviews possible optimizations to augment their cytotoxic efficiency in solid tumors.
Citation
ImmunoTargets and Therapy, 2021, 10 pp. 313 - 323
Source Title
ImmunoTargets and Therapy
Publisher
DOVE MEDICAL PRESS LTD
ISSN
2253-1556
eISSN
2253-1556
2253-1556
2253-1556
Collections
Research Team
Thor Onco Immuno Group